U.S. Markets closed

Pasithea Therapeutics Corp. (KTTA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8950-0.0106 (-1.17%)
At close: 04:00PM EDT
0.8800 -0.01 (-1.68%)
After hours: 07:27PM EDT

Pasithea Therapeutics Corp.

1111 Lincoln Road
Suite 500
Miami Beach, FL 33139
United States
702 514 4174

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Prof. Lawrence Steinman BA, M.D.Exec. Chairman & Co-Founder72.92kN/A1948
Dr. Tiago Reis MarquesCEO & Director243.75kN/A1978
Mr. Stanley M. GlossChief Financial Officer67.5kN/A1960
Dr. Yassine Bendiabdallah Ph.D.COO, Head of UK Clinics & DirectorN/AN/A1986
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Corporate Governance

Pasithea Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.